Expression of steroid hormone receptors in leiomyosarcoma of different anatomic localizations
https://doi.org/10.33667/2078-5631-2020-20-49-53
Abstract
Leiomyosarcoma (LMS) is a group of malignant mesenchymal tumors with variable behavior and prognosis. in general, 5-year overall survival rates for 64 %o, but in case of disseminated disease it decreases to 10-16 %. The main treatment modality that determines the prognosis is radical surgery. For the treatment of unresectable leiomyosarcoma, chemotherapy and targeted therapy are used. One of the alternative options for drug treatment with uterine leiomyosarcoma is hormone therapy. its use is possible with a positive status of estrogen and progesterone receptors in the tumor. The presence of steroid hormone receptor expression is a favorable prognostic factor. This article presents our own analysis of the frequency of expression of estrogen and progesterone receptors and the frequency of hormone therapy in leiomyosarcoma of different anatomic localization.
About the Authors
O. A. Rozonova
National Medical Research Centre of Oncology n.a. N.N. Blokhin
Russian Federation
Moscow
Russian Federation
Moscow
E. V. Artamonova
National Medical Research Centre of Oncology n.a. N.N. Blokhin; Russian National Research Medical University n.a. N.I. Pirogov
Russian Federation
Moscow
Russian Federation
Moscow
N. A. Kozlov
National Medical Research Centre of Oncology n.a. N.N. Blokhin
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Billingsley K. G., Burt M. E., Jara E. et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival // Ann. Surg.- 1999.-Vol. 229, No 5.-P. 602-610.
2. Farshid G., Pradhan M., Goldblum J., WeissS. Leiomyosarcoma of somatic soft tissues. A tumor of vascular origin with multivariate analysis of outcome in 42 cases// Am. J. Surg. Pathol.-2002.-Vol. 26.-P. 14-24.
3. Lamm W., Natter C., Schur S. et al. Distinctive outcome in patients with non-utenne and uterine leiomyosarcoma. BMC Cancer2014, 14: 981.
4. Stiller C. A., Trama A., Serraino D. et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project // Eur. J. Cancer.-2013.-Vol. 49, No 3.- P. 684-95.
5. Weiss S. W., Goldblum J. R. Leiomyosarcoma. In: Weiss S. W., Goldblum J. R., eds. Enzinger and Weiss's Soft Tissue Tumors. 6th ed // Philadelphia.-2014.-P. 549-568.
6. D’angelo E., Prat J. Uterine sarcomas: a review. GynecolOncol. 2010, v. 116, p. 131-139.
7. Kim H.J., Kim Y., Lee S. J., Lee J., Park S. H. Pazopan-ib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center ret-rosrective study. J Gynecol Oncol. 2018,29 (1): e3.
8. Mestirr S, Elghali MA, Bourigua R, Abdessayed N, NasriS, Amine BA, MissaouiN, Ben Maitig M, Hmissa S, Sriha B, Mokni M. Soft tissue leiomyosarcoma -diagnostics, management, and prognosis: Data of the registry cancer of the center of Tunisia. Rare Tumors. 2019. Volume 11: 1-7.
9. Harati K., Daigeler A., Lange K., Niggemann H., Strieker I., Steinau H., Lehnhardt M., Goertz O. Somatic Leiomyosarcoma of the Soft Tissues: A Single-Institutional Analysis of Factors Predictive of Survival in 164 Patients. World J Surg. 2017 Jun; 41 (6): 1534-1541. Doi: 10.1007/s00268-017-3899-5.
10. Gootee J, Sioda N, Aurit S, Curtin C, Silberstein P. Important prognostic factors in leiomyosarcoma survival: a National Cancer Database (NCDB) analysis. Clin Transl Oncol. 2019 Aug 7. DOI: 10.1007/s12094-019-02196.
11. Roberts M. E., Aynardi J. T., Chu C. S. Uterine leiomyosarcoma: A review of the literature and update on management options. GynecolOncol. 2018. Volume 151. Issue 3. P. 562-572.
12. Феденко А. А., Конев А. А., Горбунова В. А. Лечение лейомиосарком матки. Саркомы костей, мягких тканей и опухолей кожи. 2014. № 1, с. 5663. DOI: 10.18027/2224-5057-2018-8-3s2-190-203.
13. Zivanovic O., Leitao M.M., Iasonos A,. Jacks L.M., Zhou Q., Abu-Rustum N.R. et al. Stagespecific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems. JCO 2009; 27: 2066-72.
14. Zang, Y., Dong, M., Zhang, K., Gao, C., Guo, F., Wang, Y., & Xue, F. Hormonal therapy in uterine sarcomas. Cancer Medicine. 2019 Apr; 8(4): 1339-1349. DOI: 10.1002/cam4.2044.
15. Leitao M. M., Soslow R. A., Nonaka D., Olshen A. B., Aghajanian C. et al. Tissue Microarray Immunohis-tochemical Expression of Estrogen, Progesterone, and Androgen Receptors in Uterine Leiomyomata and Leiomyosarcoma. Cancer. 2004. Volume 101. Number 6. P. 1455-1462.
16. Kelley T. W., Borden E. C., Goldblum J. R. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immuno-histochemical study // Appl. Immunohistochem. Mol. Morphol.-2004.-Vol. 12, No 4.-Р. 338-341.
17. Baek M.-H., Park J.-Y., Park Y., Kim K.-R., Kim D.-Y., Suh D.-S. et al. Androgen receptor as a prognostic biomarker and therapeutic target in uterine leiomyosarcoma. Journal of Gynecologic Oncology, 2018, 29 (3).
18. Авдалян А. М. Патоморфологический и иммуногистохимический анализ лейомиомы и лейо-миосаркомы тела матки: дифференциальная диагностика и прогноз. Автореферат диссертации на соискание ученой степени доктора медицинских наук, 2013.
19. Ioffe Y. J., Li A. J., Walsh C. S., Karlan B. Y., Leuchter R., Forscher C., & Cass I. (2009). Hormone receptor expression in uterine sarcomas: Prognostic and therapeutic roles. Gynecologic Oncology, 115 (3), 466-471. DOI: 10.1016/j.ygyno.2009.08.014.
20. Thanopoulou E., Thway K., Khabra K. and Jud-son I. Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors. Clinical Sarcoma Research 2014, 4: 5, p. 1-8.
21. O’Cearbhaill, R., Zhou, Q., Iasonos, A., Soslow, R. A., Leitao, M. M., Aghajanian, C., & Hensley, M. L. (2010). Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecologic Oncology, 116 (3), 424-429. DOI: 10.1016/j.ygy-no.2009.10.064.
22. Seagle B.-L. L., Sobecki-Rausch J., Strohl A.E., Shilpi A., Grace A., Shahabi S. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study. Gynecologic Oncology, 2017, 145(1), 61-70.
23. George, S., Feng, Y., Manola, J., Nucci, M. R., Butrynski, J. E., Morgan, J. A. et al. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer, 2013. 120(5), 738-743. DOI: 10.1002/cncr.28476.
24. Slomovitz D., Trigo L., Faverio C., Brehm M., & Kyriazis G. A. A randomized phase II study of letrozole vs. Observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS). Gynecol. Oncol. Rep. 2018. 27, p. 1-4. DOI: 10.1109/cpem.2018.8501056.
25. Синячкин М. С. Оптимизация диагностики и лечения лейомиосарком мягких тканей. Автореферат диссертации на соискание ученой степени кандидата медицинских наук, 2016.
26. Carvalho J. C., Thomas D. G., Lucas D. R. Cluster Analysis of Immunohistochemical Markers in Leiomyosarcoma Delineates Specific Anatomic and Gender Subgroups. Cancer2009; 115, p: 4186-95.
27. Li L., Schuster I. P., Jacob R. et al. Potential benefit of hormonal therapy for non-uterine soft tissue sarcoma (STS) - a case report and literature review // Springerplus.-2013.- Vol. 2.- P. 536.
28. Oliva E., Carcangiu M. L., Carinelli S. G. et al. Mesenchymal tumours. In/Kurman R.J., Carcan-giu M. L., Herrington C. S., Young R. H. (Eds). WHO Classification of Tumours of Female Reproductive Organs. IARC.-Lyon.-2014.-p. 135-147.
Review
For citations:
Rozonova O.A., Artamonova E.V., Kozlov N.A. Expression of steroid hormone receptors in leiomyosarcoma of different anatomic localizations. Medical alphabet. 2020;(20):49-53. (In Russ.) https://doi.org/10.33667/2078-5631-2020-20-49-53
Views:
462
Email this article 